Tarsons Products (TARSONS) | Financial Analysis & Statements
Tarsons Products Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
913.6M
Gross Profit
620.6M
67.93%
Operating Income
47.7M
5.22%
Net Income
17.8M
1.95%
EPS (Diluted)
₹0.34
Balance Sheet Metrics
Total Assets
10.8B
Total Liabilities
4.5B
Shareholders Equity
6.3B
Debt to Equity
0.71
Cash Flow Metrics
Operating Cash Flow
100.0M
Free Cash Flow
-231.3M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Tarsons Products Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.9B | 2.9B | 2.8B | 3.0B | 2.3B |
| Cost of Goods Sold | 1.4B | 942.9M | 782.4M | 800.6M | 742.8M |
| Gross Profit | 2.5B | 2.0B | 2.0B | 2.2B | 1.5B |
| Gross Margin % | 63.1% | 68.0% | 72.2% | 73.2% | 67.4% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 203.1M | 219.6M | 137.5M | 105.0M | 82.0M |
| Other Operating Expenses | 503.8M | 349.0M | 267.2M | 257.4M | 183.8M |
| Total Operating Expenses | 706.8M | 568.6M | 404.8M | 362.4M | 265.8M |
| Operating Income | 532.8M | 633.5M | 1.0B | 1.3B | 923.8M |
| Operating Margin % | 13.6% | 21.5% | 37.1% | 44.8% | 40.5% |
| Non-Operating Items | |||||
| Interest Income | 8.9M | 17.8M | 28.9M | 13.1M | 2.9M |
| Interest Expense | 192.9M | 100.2M | 43.9M | 39.8M | 27.2M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 448.0M | 607.7M | 1.1B | 1.3B | 924.3M |
| Income Tax | 150.3M | 181.3M | 280.1M | 343.2M | 235.6M |
| Effective Tax Rate % | 33.6% | 29.8% | 25.8% | 25.4% | 25.5% |
| Net Income | 297.7M | 426.4M | 807.1M | 1.0B | 688.7M |
| Net Margin % | 7.6% | 14.5% | 28.7% | 33.6% | 30.2% |
| Key Metrics | |||||
| EBITDA | 1.3B | 1.1B | 1.4B | 1.6B | 1.1B |
| EPS (Basic) | ₹5.60 | ₹8.01 | ₹15.17 | ₹19.46 | ₹13.52 |
| EPS (Diluted) | ₹5.60 | ₹8.01 | ₹15.17 | ₹19.46 | ₹13.52 |
| Basic Shares Outstanding | 53210000 | 53210000 | 53210000 | 51740000 | 50940000 |
| Diluted Shares Outstanding | 53210000 | 53210000 | 53210000 | 51740000 | 50940000 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Tarsons Products Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 251.3M | 171.1M | 590.6M | 774.4M | 23.3M |
| Short-term Investments | 5.2M | 55.0M | 9.6M | 84.4M | - |
| Accounts Receivable | 796.2M | 778.9M | 658.0M | 651.8M | 470.4M |
| Inventory | 1.3B | 1.3B | 1.1B | 823.7M | 467.0M |
| Other Current Assets | 111.6M | 60.2M | 118.5M | 111.0M | - |
| Total Current Assets | 2.4B | 2.4B | 2.5B | 2.4B | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.9B | 1.5B | 1.1B | 924.4M | 587.9M |
| Goodwill | 967.9M | 1.0B | 5.1M | 6.6M | 5.8M |
| Intangible Assets | 317.4M | 366.0M | 5.1M | 6.6M | 5.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 604.8M | 1.3B | 1.2B | -1.0M | -530.0K |
| Total Non-Current Assets | 8.4B | 7.4B | 4.7B | 3.0B | 1.8B |
| Total Assets | 10.8B | 9.7B | 7.3B | 5.4B | 3.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 157.1M | 146.4M | 96.5M | 129.5M | 59.8M |
| Short-term Debt | 1.3B | 1.6B | 299.5M | 122.8M | 301.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 72.1M | 40.4M | 38.9M | 46.8M | 10.0K |
| Total Current Liabilities | 1.8B | 2.1B | 629.2M | 349.1M | 418.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.1B | 1.1B | 807.4M | 93.9M | 33.2M |
| Deferred Tax Liabilities | 93.9M | 92.2M | 54.1M | 43.6M | 32.8M |
| Other Non-Current Liabilities | 520.0M | 245.2M | 72.8M | 1.0M | 530.0K |
| Total Non-Current Liabilities | 2.7B | 1.5B | 934.6M | 194.8M | 98.1M |
| Total Liabilities | 4.5B | 3.6B | 1.6B | 544.0M | 516.1M |
| Equity | |||||
| Common Stock | 106.4M | 106.4M | 106.4M | 106.4M | 1.9M |
| Retained Earnings | 4.7B | 4.5B | 4.1B | 3.3B | 2.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 6.3B | 6.1B | 5.7B | 4.9B | 2.4B |
| Key Metrics | |||||
| Total Debt | 3.4B | 2.7B | 1.1B | 216.6M | 335.0M |
| Working Capital | 668.5M | 221.2M | 1.9B | 2.1B | 710.0M |
Balance Sheet Composition
Tarsons Products Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 448.0M | 607.7M | 1.1B | 1.3B | 924.3M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -34.1M | 93.4M | -320.7M | -480.1M | -163.3M |
| Operating Cash Flow | 571.9M | 767.0M | 769.5M | 890.9M | 783.4M |
| Investing Activities | |||||
| Capital Expenditures | -1.5B | -1.8B | -1.9B | -1.3B | -641.6M |
| Acquisitions | 0 | -651.4M | - | - | - |
| Investment Purchases | -835.0M | -49.0M | 0 | -1.8B | -626.9M |
| Investment Sales | 875.6M | 4.2M | 69.9M | 1.7B | 626.9M |
| Investing Cash Flow | -1.5B | -2.5B | -1.8B | -1.4B | -641.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | -220.0M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 1.6B | 855.3M | 1.1B | 433.2M | 65.2M |
| Debt Repayment | -14.9B | -827.6M | -249.8M | -2.9B | -1.5B |
| Financing Cash Flow | -13.7B | 1.0B | 791.9M | -1.2B | -1.6B |
| Free Cash Flow | -374.7M | -816.3M | -1.1B | -485.0M | 38.3M |
| Net Change in Cash | -14.6B | -719.8M | -257.8M | -1.7B | -1.5B |
Cash Flow Trend
Tarsons Products Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
55.45
Forward P/E
16.29
Price to Book
1.81
Price to Sales
2.72
PEG Ratio
-13.72
Profitability Ratios
Profit Margin
4.91%
Operating Margin
6.01%
Return on Equity
4.72%
Return on Assets
2.76%
Financial Health
Current Ratio
1.03
Debt to Equity
63.18
Beta
0.13
Per Share Data
EPS (TTM)
₹3.82
Book Value per Share
₹116.95
Revenue per Share
₹77.94
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TARSONS | 11.0B | 55.45 | 1.81 | 4.72% | 4.91% | 63.18 |
| Poly Medicure | 151.0B | 43.53 | 5.17 | 12.24% | 19.51% | 8.17 |
| Dr Agarwal's Health | 138.9B | 109.80 | 7.17 | 4.33% | 6.38% | 48.68 |
| Laxmi Dental | 10.4B | 44.95 | 4.43 | 15.22% | 8.76% | 3.88 |
| Prevest Denpro | 5.4B | 27.33 | 4.69 | 17.20% | 27.78% | 0.00 |
| Shree Pacetronix | 532.1M | 20.75 | 3.24 | 5.44% | 12.10% | 32.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.




